Artwork
iconShare
 
Manage episode 522168375 series 3653549
Content provided by Ed Delesky, MD and Nicole Aruffo, RN, Ed Delesky, MD, Nicole Aruffo, and RN. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ed Delesky, MD and Nicole Aruffo, RN, Ed Delesky, MD, Nicole Aruffo, and RN or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.

We unpack new GLP-1 pricing, coverage hurdles, and whether cash-pay programs make these meds more reachable for diabetes, obesity, and sleep apnea care. Along the way we share candid pros and cons of injections, tease future oral options, and weigh real tradeoffs.
• current cash-pay pricing from major manufacturers
• differences between Wegovy, Ozempic, and Zepbound
• tighter insurance coverage and prior authorization burden
• fears about injections and route-of-administration bias
• potential oral GLP-1 timelines and cost impact
• framing obesity as a chronic, treatable disease
• practical tips to explore HSA or FSA options
• how to decide if the monthly cost is worth it
Support the show

Subscribe to Our Newsletter!

Production and Content: Edward Delesky, MD & Nicole Aruffo, RN
Artwork: Olivia Pawlowski

  continue reading

Chapters

1. Cold Open And Host Banter (00:00:00)

2. Dancing With The Stars Debate (00:02:00)

3. Gifts, Humor, And Holiday Bits (00:06:30)

4. TV Recs And Dinner Talk (00:10:20)

5. Retail Tech And Coffee Shop Finds (00:14:45)

6. Main Topic: GLP-1 Price Drops (00:17:10)

7. Coverage Limits And Cash-Pay Offers (00:20:30)

8. Cost, Value, And Treatment Tradeoffs (00:24:00)

9. Shots Versus Pills And New Orals (00:27:30)

91 episodes